The Stand Up To Cancer Translational Cancer Research Grants represent a new, focused effort to affect advances in cancer research as rapidly as possible through the creation of collaborative, international translational cancer research “Teams.” These teams are typically smaller than the SU2C Dream Teams, but have the same overarching goal of pursuing the most promising research, accelerating the discovery of new therapies for cancer patients and/or advancing efforts in cancer prevention research.
On Aug. 2, 2012, SU2C announced the first team to receive a Translational Cancer Research Grant in collaboration with the Dutch Cancer Society ( DCS). The grant is supported with money raised in connection with a November 2010 Dutch version of the Stand Up To Cancer televised fundraising event, Sta Op Tegen Kanker, which was broadcasted in the Netherlands under the auspices of the DCS. The Sta Op Tegen Kanker International Translational Cancer Research Team includes researchers from the three largest cancer centers in the Netherlands: the Netherlands Cancer Institute, Erasmus MC, and UMC Utrecht. Funding of €1.2 million will support the team over a four-year period.
On April 7, 2014, SU2C announced a second team to receive a Translational Cancer Research Grant, this time in collaboration with the Farrah Fawcett Foundation. The SU2C-Farrah Fawcett Foundation Human Papillomavirus (HPV) Translational Research Team will receive $1.2 million in funding over three years for a project that will focus on patients with HPV-driven cancers (including anal, cervical, and head and neck cancers).
2014 Translational Grant
SU2C-Farrah Fawcett Foundation Translational Team: Therapeutic CD8 Vaccines Against Conserved E7 HPV Epitopes Identified by MS
Leader: Ellis L. Reinherz, MD, Dana-Farber Cancer Institute
Co-leader: Robert I. Haddad, MD, Dana-Farber Cancer Institute
Grant Term: July 2014 – June 2017 Total Funding: $1.2 million
2013 Translational Team
SU2C-Dutch Cancer Society International Team: Prospective Use of DNA-guided Personalized Cancer Treatment
Leader: Emile E. Voest, MD, PhD, University Medical Center Utrecht in the Netherlands [Current institution: The Netherlands Cancer Institute]
Co-leader: René Bernards, PhD, The Netherlands Cancer Institute
Grant Term: April 2014 – March 2018 Total Funding: €1.2 million
Email: SU2C@aacr.org (for non-media related SU2C questions)
Updated: August 2016